Sun Pharma's growth pill: Specialising in specialty and scaling in India

Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company, Sun......

Israel conflict unlikely to impact trade of pharma firms

Indian pharmaceutical firms foresee minimal disruptions in trade with Israel despite escalating regional tensions. Photograph: Yves Herman/Reuters Rising crude prices and export shipping insurance......

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a......

Will Sudhir Valia, Suraksha's 'deal maker' manage to bag Jaypee Infra?

Suraksha started by funding developers for projects, and then evolved into realty angel investing. Dev Chatterjee reports. IMAGE: Suraksha Smart City - Vasai-Virar's biggest township under......